Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Yang JC, et al. Among authors: yamamoto n. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12. Lancet Oncol. 2015. PMID: 25589191 Free article. Clinical Trial.
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M; West Japan Thoracic Oncology Group (WJTOG). Yamamoto N, et al. Cancer. 2006 Aug 1;107(3):599-605. doi: 10.1002/cncr.22024. Cancer. 2006. PMID: 16804877 Free article. Clinical Trial.
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Maruyama R, et al. Among authors: yamamoto n. J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185. J Clin Oncol. 2008. PMID: 18779611 Clinical Trial.
Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
Shukuya T, Takahashi T, Tamiya A, Ono A, Igawa S, Tsuya A, Nakamura Y, Murakami H, Naito T, Kaira K, Endo M, Yamamoto N. Shukuya T, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147. Epub 2009 Jan 12. Jpn J Clin Oncol. 2009. PMID: 19139038
[Lung cancer].
Ayabe E, Kaira K, Yamamoto N. Ayabe E, et al. Among authors: yamamoto n. Gan To Kagaku Ryoho. 2009 Jan;36(1):21-5. Gan To Kagaku Ryoho. 2009. PMID: 19151561 Japanese.
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. Goto K, et al. Among authors: yamamoto n. J Thorac Oncol. 2012 Jan;7(1):115-21. doi: 10.1097/JTO.0b013e3182307f98. J Thorac Oncol. 2012. PMID: 21900837 Free article. Clinical Trial.
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Atagi S, et al. Among authors: yamamoto n. Lancet Oncol. 2012 Jul;13(7):671-8. doi: 10.1016/S1470-2045(12)70139-0. Epub 2012 May 22. Lancet Oncol. 2012. PMID: 22622008 Clinical Trial.
The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.
Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N. Akamatsu H, et al. Among authors: yamamoto n. Am J Clin Oncol. 2014 Apr;37(2):144-7. doi: 10.1097/COC.0b013e31826e04f9. Am J Clin Oncol. 2014. PMID: 23211219
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Kogure Y, et al. Among authors: yamamoto n. J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5. J Thorac Oncol. 2013. PMID: 23575412 Free article.
6,248 results